Myostatin and sarcopenia

Opportunities and challenges - A mini-review

Thomas A. White, Nathan K LeBrasseur

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The progressive loss of skeletal muscle mass, strength and/or function with advancing age, termed sarcopenia, poses a major threat to independence and quality of life. Therefore, there is significant merit in better understanding the biology of sarcopenia and developing therapeutic interventions to prevent, slow or reverse its progression. Since the discovery of myostatin, a potent negative regulator of growth that is highly enriched in skeletal muscle, there has been great interest in it as a potential mediator of sarcopenia as well as a therapeutic target. The complex biology of myostatin, the promise of myostatin inhibition as an effective means to counter sarcopenia, and the challenges facing its clinical translation are reviewed herein.

Original languageEnglish (US)
Pages (from-to)289-293
Number of pages5
JournalGerontology
Volume60
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Myostatin
Sarcopenia
Skeletal Muscle
Muscle Strength
Quality of Life
Therapeutics
Growth

Keywords

  • Aging
  • Atrophy
  • Diabetes
  • Drug discovery
  • Frailty
  • Growth and differentiation factor
  • Obesity
  • Skeletal muscle

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology

Cite this

Myostatin and sarcopenia : Opportunities and challenges - A mini-review. / White, Thomas A.; LeBrasseur, Nathan K.

In: Gerontology, Vol. 60, No. 4, 2014, p. 289-293.

Research output: Contribution to journalArticle

@article{16516e32881e47c885312fcc921496be,
title = "Myostatin and sarcopenia: Opportunities and challenges - A mini-review",
abstract = "The progressive loss of skeletal muscle mass, strength and/or function with advancing age, termed sarcopenia, poses a major threat to independence and quality of life. Therefore, there is significant merit in better understanding the biology of sarcopenia and developing therapeutic interventions to prevent, slow or reverse its progression. Since the discovery of myostatin, a potent negative regulator of growth that is highly enriched in skeletal muscle, there has been great interest in it as a potential mediator of sarcopenia as well as a therapeutic target. The complex biology of myostatin, the promise of myostatin inhibition as an effective means to counter sarcopenia, and the challenges facing its clinical translation are reviewed herein.",
keywords = "Aging, Atrophy, Diabetes, Drug discovery, Frailty, Growth and differentiation factor, Obesity, Skeletal muscle",
author = "White, {Thomas A.} and LeBrasseur, {Nathan K}",
year = "2014",
doi = "10.1159/000356740",
language = "English (US)",
volume = "60",
pages = "289--293",
journal = "Gerontology",
issn = "0304-324X",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Myostatin and sarcopenia

T2 - Opportunities and challenges - A mini-review

AU - White, Thomas A.

AU - LeBrasseur, Nathan K

PY - 2014

Y1 - 2014

N2 - The progressive loss of skeletal muscle mass, strength and/or function with advancing age, termed sarcopenia, poses a major threat to independence and quality of life. Therefore, there is significant merit in better understanding the biology of sarcopenia and developing therapeutic interventions to prevent, slow or reverse its progression. Since the discovery of myostatin, a potent negative regulator of growth that is highly enriched in skeletal muscle, there has been great interest in it as a potential mediator of sarcopenia as well as a therapeutic target. The complex biology of myostatin, the promise of myostatin inhibition as an effective means to counter sarcopenia, and the challenges facing its clinical translation are reviewed herein.

AB - The progressive loss of skeletal muscle mass, strength and/or function with advancing age, termed sarcopenia, poses a major threat to independence and quality of life. Therefore, there is significant merit in better understanding the biology of sarcopenia and developing therapeutic interventions to prevent, slow or reverse its progression. Since the discovery of myostatin, a potent negative regulator of growth that is highly enriched in skeletal muscle, there has been great interest in it as a potential mediator of sarcopenia as well as a therapeutic target. The complex biology of myostatin, the promise of myostatin inhibition as an effective means to counter sarcopenia, and the challenges facing its clinical translation are reviewed herein.

KW - Aging

KW - Atrophy

KW - Diabetes

KW - Drug discovery

KW - Frailty

KW - Growth and differentiation factor

KW - Obesity

KW - Skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=84903520673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903520673&partnerID=8YFLogxK

U2 - 10.1159/000356740

DO - 10.1159/000356740

M3 - Article

VL - 60

SP - 289

EP - 293

JO - Gerontology

JF - Gerontology

SN - 0304-324X

IS - 4

ER -